News Releases

News Category

Year

24 Sep '2020

Advaxis Announces FDA Clearance of New IND for ADXS-504 for Treatment of Prostate Cancer

Strategic transition to Investigator sponsored IND from previously announced Advaxis sponsored IND Initiation of investigator sponsored Phase 1 study of ADXS-504 in prostate cancer on-track for Q4 2020 PRINCETON, N.J. , Sept. 24, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc.

PDF Version

10 Sep '2020

Advaxis Reports Third Quarter Ended July 31, 2020 Financial Results and Provides a Business Update

Strategic expansion of ADXS-503 HOT program in NSCLC to explore potential to enhance and or restore sensitivity to checkpoint inhibitors Enrolling in Phase 1/2 Study efficacy expansion of ADXS-503 in NSCLC based on sustained and durable clinical responses in first two of three evaluable patients

PDF Version

04 Sep '2020

Advaxis Announces Resignation of Chief Financial Officer

PRINCETON, N.J. , Sept. 04, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products today announced that Molly Henderson , Executive Vice President and Chief Financial Officer, has

PDF Version

27 Aug '2020

Advaxis to Present Corporate Overview at the LD Micro 500 Virtual Conference

PRINCETON, N.J. , Aug. 27, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS ), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that Kenneth A. Berlin , President and Chief Executive Officer of Advaxis , will

PDF Version

03 Aug '2020

Advaxis Announces Common Stock Purchase Agreement for up to $20 Million with Lincoln Park Capital

PRINCETON, N.J. , Aug. 03, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products today announced that it has entered into a common stock purchase agreement for up to $20 million with

PDF Version

23 Jun '2020

Advaxis to be Featured in “Grand Rounds: a Webinar in Biotech and Specialty Pharma,” Hosted by Alliance Global Partners

PRINCETON, N.J. , June 23, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS ), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that Kenneth A. Berlin , President and Chief Executive Officer of Advaxis , will be

PDF Version

11 Jun '2020

Advaxis Reports Second Quarter Ended April 30, 2020 Financial Results and Provides a Business Update

Expanding Phase 1/2 Study of ADXS-503 in NSCLC based on sustained and durable clinical responses in first two patients from Part B combination arm with KEYTRUDA® Increasing patient enrollment in Part B and initiating Part C to move into first-line regimen with KEYTRUDA® in patients ineligible for

PDF Version

01 Jun '2020

Advaxis to Host Second Quarter Financial Results and Business Update Conference Call on Thursday, June 11, 2020

PRINCETON, N.J. , June 01, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, announced today that it will release financial results for the second quarter ended April 30, 2020

PDF Version

14 May '2020

Advaxis Announces Updated Positive Clinical and Biomarker Data from Ongoing Phase 1/2 ADXS-503 Trial in NSCLC

Sustained clinical benefit seen in patients treated with ADXS-503 in combination with KEYTRUDA® after 16 weeks, including a partial response and stable disease in patients who had most recently progressed on KEYTRUDA® Positive preliminary immunogenicity data with CD8+ T cells generated in all of

PDF Version

13 Mar '2020

Advaxis Reports First Quarter Ended January 31, 2020 Financial Results and Provides a Pipeline Update

PRINCETON, N.J. , March 13, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products today announced an update on its clinical pipeline and financial results for the first quarter ended

PDF Version

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 18